Riscul trombozei recurente la pacienţii cu sindrom antifosfolipidic secundar LES

Abstract

Objectives: to evaluate the significance of Pselectin and sCD40L levels for the evolution of venous and arterial recurrent thrombosis in patients (pts.) with antiphospholipid syndrome (APS) secondary to systemic lupus erythematosus (LES). Methods: 20 pts. with APS secondary to LES diagnosed according to revised Sapporo classification for APS criteria, mean age 47.87 (18-74) years, 16 women and 4 men were followed 24 months for the evolution with recurrent thrombosis. Serum IgG or IgM anticardiolipin antibodies (aCL), serum P-selectin, and sCD40L (R&D Minneapolis, USA) levels were assessed using the standardized ELISAs method at baseline and after 12 months. Statistics: t-test/ANOVA, logistic regression. Results: APS pts. with a history of thrombosis had higher Pselectin levels than APS pts. without a history of thrombosis (256.63±145.79 versus 121.85±101.47ng/dl; p=0.04). Pts. with APS showed higher sCD40L levels than did subjects without a history of thrombosis (15402.29±15290.62 versus 9508.99±6164.03ng/dl; p=0.34). No significant correlation was observed between aCL levels in patients with recurrent thrombosis and APS patients without recurrent thrombosis (194.25±237.59 versus 52.57±10.64UPL; p=0.13). Conclusions: Pselectin seems to be a serologic test most likely correlated with recurrent thrombosis in pts. with APS associated with LES.